Goldman Sachs
ANTX icon

Goldman Sachs’s AN2 Therapeutics ANTX Stock Holding History

Goldman Sachs’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-224,185
Closed -$482K – 5801
2024
Q2 		$482K Buy
224,185
+195,815
+690% +$466K ﹤0.01% 4854
2024
Q1 		$92.2K Buy
28,370
+14,324
+102% +$156K ﹤0.01% 5256
2023
Q4 		$288K Buy
+14,046
New +$235K ﹤0.01% 5026
2023
Q3 		– Sell
-39,107
Closed -$332K – 5523
2023
Q2 		$332K Buy
+39,107
New +$281K ﹤0.01% 4963
2022
Q2 		– Sell
-19,497
Closed -$294K – 6438
2022
Q1 		$294K Buy
+19,497
New +$296K ﹤0.01% 5669

Other funds holding ANTX

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs's ANTX Position: Q3 2024 in Review

Goldman Sachs sold out of AN2 Therapeutics (ANTX) in Q3 2024, closing a stake of 224,185 shares — an estimated $482K sold.

Goldman Sachs first reported a position in ANTX in Q1 2022 and held it in 5 quarters. The position peaked at $482K in Q2 2024. 31 funds tracked by Wall St. Rank hold ANTX as of Q3 2024.

  • Goldman Sachs reported no remaining AN2 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Goldman Sachs sold 224,185 AN2 Therapeutics shares in Q3 2024, an estimated $482K.
  • Goldman Sachs first reported a position in AN2 Therapeutics in Q1 2022 and held it in 5 quarters.
  • Goldman Sachs's AN2 Therapeutics position peaked at $482K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q3 2024.

Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.